Its Over, page-341

Biotron(BIT) successful Phase 2 Clinical trial for HIV-1 treatment explained:

“As we have always maintained, eradication of this virus population fromthese reservoirs is central to an

eventual HIV1 cure.

This important trial builds on a solid foundation of previously reportedlaboratory studies that showed

that BIT225 attacks HIV1 in macrophage cells that current drugs cannotaccess.

Unless macrophage cells are cleared of HIV1 virus, a cure is notpossible. Current drugs do an excellent job

of taking HIV1 in the blood to undetectablelevels but do not clear virus in macrophages

These cells, whichreside in the body’s tissues, produce low levelsof HIV1, even in patients taking current antiretroviral drugs

This means that the infection persists. Patients can’t stop takingantiretroviral drugs; if they do, the virus

quickly rebounds to high levels

Clearing out virusfrom these macrophage reservoir cells is an important key step towardseradicating HIV1 completely.

Biotron’s data indicate that BIT225 could form part of a cure strategyfor HIV1 infection.

The clinical trial also showed that BIT225 reduced an importantmacrophage associated protein (sCD163)

that correlates with severity of disease….”

Incoming weeks, Biotron will brief potential pharmaceutical partners on the trialoutcomes.

We believethat the successful results from this study will facilitate commercialisationnegotiations with these parties

In parallel, the Company expects to present the detailed data from theclinical trial at conferences in late 2018/early 2019

The downdraft is being felt across small/microcaps today. Being ahead of the curve helped saved 5.9% in returns compared against 'doing nothing" and holding onto all positions and this also assumed that the current loss position in BIT was not entered into.

COVERAGE DATE	STOCKS	PRICE ON COVERAGE DATE	PRICE @MIDDAY	GAIN%
3/10	BIT	$          0.140	$      0.122	-12.9%
26/9	CXL	$          0.735	$      0.750	2.0%
20/9-close	4DS	$          0.064	$      0.066	3.1%
3/9	NST	$          8.140	$      8.450	3.8%
29/8-close	SVA	$          0.037	$      0.035	-5.4%
20/8-close	NGI	$          5.810	$      5.160	-11.2%
8/8-close	SFC	$        15.050	$    16.470	9.4%
6/8-close	CGL	$          7.080	$      7.930	12.0%
31/7-close	MYE	$          1.180	$      1.435	21.6%
30/7-close	MP1	$          4.370	$      3.990	-8.7%
26/7-close	SKF	$          0.150	$      0.200	33.3%
24/7	ZEN	$          1.060	$      0.790	-25.5%
23/7-close	CXL	$          0.630	$      0.830	31.7%
17/7	COE	$          0.445	$      0.465	4.5%
13/7-close	SHL	$        26.500	$    25.360	-4.3%
29/6	BYE	$          0.340	$      0.350	2.9%
28/6-close	ATC	$          0.195	$      0.140	-28.2%
18/6-close	A2M	$        10.780	$    11.490	6.6%
18/6-close	CGC	$          8.750	$      7.240	-17.3%
14/6-close	NZK	$          2.240	$      2.480	10.7%
4/6-close	BUB	$          0.830	$      0.625	-24.7%
15/5-close	SW1	$          0.410	$      0.380	-7.3%
14/5-close	RHC	$        65.420	$    55.250	-15.5%
9/5-close	FYI	$          0.145	$      0.115	-20.7%
3/5-close	4DS	$          0.057	$      0.100	75.4%
2/5-close	PME	$          8.150	$    10.860	33.3%
1/5	TTT	$          1.540	$      1.590	3.2%
30/4-close	CTD	$        24.880	$    33.540	34.8%
18/4-close	CLV	$          1.030	$      1.575	52.9%
18/4-close	VIV	$          0.054	$      0.043	-20.4%
11/4-close	APX	$          8.820	$    15.010	70.2%
11/4-close	BHP	$        29.440	$    32.385	10.0%
11/4-close	PPS	$          0.595	$      1.135	90.8%
11/4	PTB	$          0.545	$      0.625	14.7%
Return @	9.53%	assuming @ $1k even per stock